RPL13AP17

Across TCGA pan-cancer cohorts, RPL13AP17 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated RPL13AP17 data layer.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RPL13AP17 RNA is associated with better overall survival. In most high-consensus cancer types, elevated RPL13AP17 expression acts as an unfavorable survival marker, although some lineages such as LUAD and SKCM show a favorable association.

LUAD, SKCM, and COAD are the cancer types where RPL13AP17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.435	0.304	<.001	58	view →
SKCM	OS	Tertile	II,III,IV	0.875	0.670	.002	49	view →
COAD	OS	Tertile	All	0.808	0.548	.009	39	view →
CESC	OS	Tertile	II,III,IV	0.692	0.859	.002	36	view →
ACC	OS	Tertile	All	0.725	0.913	.022	36	view →
KIRC	DFS	Tertile	IV	0.196	0.387	.009	34	view →
LUSC	DFS	Median	III,IV	0.552	0.755	.012	22	view →
LIHC	OS	Tertile	II,III,IV	0.305	0.652	.005	21	view →
DLBC	OS	Tertile	III,IV	0.272	1.000	.017	16	view →
KIRP	OS	Tertile	All	1.000	0.690	.026	12	view →
ESCA	DFS	Median	All	0.538	0.858	.046	9	view →
BLCA	DFS	Tertile	IV	0.239	0.494	.043	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

RPL13AP17–LUAD (OS)

Open the LUAD breakdown →